Orthofix launches new bioactive synthetic graft

Biologics

Orthofix earned FDA 510(k) clearance for its OsteoCove advance bioactive synthetic graft, the company said Oct. 12.

The newly launched bone graft is available in putty and strip configurations, according to a news release. OsteoCove has a specialized granule surface topography for bone forming and is made of biphasic ceramic granule comprised of β-tricalcium phosphate and hydroxyapatitecombined with type-I bovine collagen.

"With the introduction of OsteoCove, we expect strong growth in this large market segment as we continue to deliver on our commitment to provide surgeons a comprehensive offering of biologic solutions to meet the needs of their patients," Tyler Lipschultz, President of global biologics, said in the release.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers